Is Jade Biosciences (JBIO) Fairly Valued After Its Recent Pullback?

Jade Biosciences (JBIO) heads into a busy September, having been scheduled to present at Wells Fargo’s 21st Annual Healthcare Conference on 8 September and at Citigroup’s Biopharma Back to School Summit on 9 September.

Recent trading has been choppy for Jade Biosciences, with the share price at US$17.89 after a 1-day share price return that declined 6.53% and a 30-day share price return that fell 27.60%. However, the 90-day share price return is up 15.20% and the 1-year total shareholder return is very large, pointing to earlier momentum that now looks to be cooling in the near term.

Scan peer biotechs reacting to the same conference circuit and see which ones screen as potential breakouts using our curated 15 high quality undiscovered gems.

After a sharp pullback, yet still a very large 1 year return, Jade Biosciences now sits at US$17.89 with no revenue and ongoing losses. Does that profile still offer enough upside potential to compensate for the risk?

Preferred price to book of 2.6x for Jade Biosciences: Is it justified?

On a simple yardstick, Jade Biosciences trades on a price to book ratio of 2.6x, which looks low against some peers yet slightly rich versus the broader US biotech group, given the quoted averages in the data.

The P/B metric compares the market value of the equity to the accounting value of net assets on the balance sheet. For a pre revenue biotech such as Jade Biosciences, this often reflects how investors weigh the pipeline, the cash runway, and the probability that current programs ever translate into commercial products, rather than any current earnings power.

Against its direct peer set, JBIO screens as good value, with a P/B of 2.6x compared with a peer average of 64.4x. In sharp contrast, the same 2.6x level screens as a little expensive compared with the wider US biotechs sector, where the average is 2.3x. This shows how sensitive the story can be to which comparison group is used.

See what the numbers say about this price — find out in our valuation breakdown.

Result: Price to book ratio of 2.6x (ABOUT RIGHT)

Still, the story around Jade Biosciences can change quickly if the phase 1 JADE101 trial disappoints or if cash burn outpaces access to fresh funding.

Find out about the key risks to this Jade Biosciences narrative.

Next Steps

Sentiment around Jade Biosciences is mixed right now. If you feel pressed for time, use that urgency to test the data yourself and pressure check the story against the 4 important warning signs.

Looking for more investment ideas beyond Jade Biosciences?

If you want to turn this research mindset into a habit, broaden your watchlist with a few focused screens that surface fresh opportunities fast.

• Target income first and scan for companies that aim to support sizeable payouts through the 6 dividend fortresses.
• Hunt for potentially mispriced quality and see which businesses the market prices below their fundamentals with the 32 high quality undervalued stocks.
• Prioritise resilience and filter for companies with stronger balance sheets and fundamentals using the list of solid balance sheet and fundamentals (23 results).

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com